摘要:
An application container (1) of the present invention includes: an inner plug member (20) mounted on a mouth portion (10) of a container main body (2) and formed with a communication hole (21) and a discharge hole (22); a holder (30) that includes an accommodating portion (31) and a plug body (35) and is formed with a communication path (40) between the holder (30) and the inner plug member (20); an application member (50) disposed in the accommodating portion (31); a biasing member (60) configured to bias the holder (30) upward with respect to the inner plug member (20); an overcap (4) mounted on the mouth portion (10) of the container main body (2); and a seal portion (80) configured to block communication between the communication path (40) and an outside, in a state where the overcap (4) is removed from the mouth portion (10) and the plug body (35) closes the communication hole (21).
摘要:
The present invention provides a method for producing a difluoromethylene compound and an intermediate thereof, which are useful in the field of pharmaceuticals. Specifically provided is a method for producing a difluoromethylene compound, including a step of allowing a compound represented by formula (6): [wherein L1 represents a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a cycloalkyl group, a lower alkoxy group, a halo-lower alkoxy group, or a hydroxy lower alkyl group; R1 represents a lower alkyl group, a halogen atom, a halo-lower alkyl group, a cycloalkyl group, a cyano group, or a hydroxy lower alkyl group; and W represents a nitrogen atom or a methine group] to react with a compound represented by formula (7): [wherein R2 represents a lower alkyl group, a halo-lower alkyl group, a cycloalkyl group, a lower alkenyl group, or an aralkyl group; and R3 represents a chlorine atom, a bromine atom, or an iodine atom].
摘要:
A compound having an URAT1 inhibitory activity, and an URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition containing the compound. More specifically, a compound represented by the formula (I): wherein R1 is -Q1-A1 or the like; R2 is a hydrogen atom, a halogen atom, a lower alkyl group or the like; W1, W2, W3 and W4 are each independently a nitrogen atom or a methine group optionally having substituents, or the like; X and Y are each a single bond, an oxygen atom or the like; Z is a hydroxyl group or COOR3 or the like.
摘要:
The present invention herein provides a compound which promotes drug-permeation into nails. A penetrating promoter comprises, for instance, the following formulas. R1, R2 and R3 are alkyl groups having a carbon number of 1 to 15 and have OH groups at their ends.
摘要:
The present invention herein provides a 2-pyridone derivative which has a cell adhesion-inhibitory activity and which is useful for preventing and/or treating pathema or disease conditions including, for instance, inflammations which relate to leukocytic infiltration. The 2-pyridone derivative is a compound represented by the following general formula (1). In the formula, R1 represents, for instance, a phenyl or pyridyl group, R2 represents, for instance, a phenyl group, R3 represents, for instance, a lower alkyl group, R4 represents, for instance, a lower alkyl group, R5 represents, for instance, a lower alkyl group, and R6 represents, for instance, a lower alkyl group.
摘要:
A pharmaceutical preparation for rectal administration by which a drug is retained in the affected region or the lower region of the rectum, where the drug is sustained-released is disclosed. The present invention is a pharmaceutical preparation for rectal administration comprising a coated drug-supported particle dispersed in a base, wherein the coated drug-supported particle is what a drug-supported porous microparticulate carrier is coated with a water-soluble polymer having a certain viscosity.
摘要:
The present invention provides a compound having a hematopoietic prostaglandin D synthase (H-PGDS) inhibitory activity and being useful for preventing or treating a disease involving the enzyme, and a pharmaceutical composition comprising the compound. Specifically, the present invention provides a compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof:
[wherein R1 represents a hydrogen atom and the like, R2 represents a hydrogen atom and the like, R3 represents a hydrogen atom and the like, R4 represents a hydrogen atom and the like, R5 represents a hydrogen atom and the like, W represents an oxygen atom and the like, and X represents a C1-6 alkyl group and the like.]
摘要:
The present invention has an object to provide a simpler and quicker method for diagnosing tinea, method for detecting a Trichophyton, or method for detecting the Trichophyton gene. Use of at least four kinds of specific primers each designed based on a DNA sequence of the Trichophyton gene makes it possible to simply and quickly detect the Trichophyton gene.
摘要:
The present invention provides a technique that allows a pharmaceutical composition, preferably for external use, containing luliconazole or the like to contain luliconazole or the like at a high concentration, and suppresses the precipitation thereof over time. The present invention uses a polyethylene glycol having an average molecular weight of 380 to 420 represented by a formula HOCH2(CH2OCH2)nCH2OH (where n is an integer), ethanol, benzyl alcohol, lactic acid, propylene carbonate, and acetone in combination with the luliconazole or the like.